Diabetes is the fastest-growing cause of inpatient and surgical care costs in the world. Worldwide spending on diabetic care already exceeds $400 billion annually, with 43% of these costs coming from hospital care in Europe and the United States. Over 40% of patients admitted to hospital are now at diabetic risk. Despite this, techniques for controlling glucose levels in hospitalized patients have remained unchanged for nearly three decades, and are too imprecise, labor-intensive, and coarsely implemented to address the growing need.
The Admetsys Smart Pancreas™ measure and maintains a hospitalized diabetics blood sugar levels in real time so their blood sugar mirrors that of a healthy patient.
Proper control of blood glucose levels and avoidance of harmful low levels saves lives (34% mortality reduction), decreases complications (by 40–50% over numerous co-morbidities), and speeds recovery (by 1.8 days in critical care patients).
Admetsys has conducted three FDA approved clinical trials using fully-engineered prototype devices, demonstrating 97% target glucose control (80–125 mg/dL) and 100% prevention of hypoglycemia (<70 mg/dL). The above data was recently presented at the American Diabetes Association 76th Scientific Sessions
How do we score?
Average Judge Score
7 judges have scored this entry. The highest possible score is 5 .3.9
We divide the average judge score with the maximum score possible and add 1 to create a multiplier.1.8
We apply the judge multiplier to the total number of crowd votes.5.3